The stock market pullback and lackluster IPO market have weighed on biotech venture financing--but only a bit. The sector is still on track for its second…

Roivant Sciences and Plexcera Therapeutics have today launched a new biotech company with a singular focus on the ultrarare condition known as Farber disease,…

A year after the small, early-stage Californian IBD biotech Protagonist Therapeutics managed to raise $40 million, the company is now seeking to go public with…

Flagship Ventures hopes to create a new immune-microbiome company that will have a candidate in the clinic next year--through the combination of a pair of its…

Early-stage Australian biotech AdAlta, which is targeting the lung-scarring disease idiopathic pulmonary fibrosis, is seeking to raise AU$10 million ($7.5…

Christine Placet has rounded up money for an ophthalmic gene therapy company, her first venture since leading Trophos to a $470 million takeover by Roche.

It’s an awkward age, to be 15. But that’s exactly where we are with the Fierce 15 this year.

Only 12 IPOs made it out last quarter from U.S. venture-backed companies. Of those, 9 were for biotech companies.